In episode 292, Mike and James delve into COPD – we briefly discuss smoking cessation and then all the evidence behind the multitude of different puffers. At the end we leave the audience hanging as we plan to discuss how to actually use these agents in the next podcast.
Show notes
In episode 291, James and Mike welcome back the smoking hot Mike Kolber to talk about the role of electronic cigarettes in helping smokers decrease smoking. We find out that e-cigarettes do seem to help some smokers quit smoking but the long-term adverse effects are unknown. At the end of the podcast all three of us, in the name of science, decide to take up smoking to do an n-of-3 trial of e-cigarettes but our attempt goes out the windows when the fire alarms go off.
Show notes
Tools For Practice
Electronic Cigarettes – Hoot that helps, hurts, or just hype?
In episode 290, James and Mike address listener demands for a discussion on the latest diabetes outcomes trial that looked at empagliflozin, a new class of medications for type-2 diabetes. This study actually showed the group who received this new drug had a reduction in CVD events and other clinically important outcomes. While this is a good finding, upcoming trials of other medications in this class will help put this drug into a context.
Show notes
1) EMPA-REG OUTCOME
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type-2 Diabetes
THE NUTRITION PROPOSITION BOOK
Check it out at nutritionproposition.com and think about picking up a copy on Amazon. All the evidence you ever wanted about nutrition and the only nutrition book that won’t tell you what to eat.
This pragmatic trial is now recruiting in BC. Make a difference and get involved with pragmatic trials (www.pragmatictrials.ca)
